Diffusion Pharmaceuticals, a clinical-stage drug-development company, has begun to enroll patients in a Phase I/II clinical trial of its lead drug candidate, trans sodium crocetinate.

Diffusion Pharmaceuticals has reported strong results from Phase I trial of trans sodium crocetinate, which was found to be well-tolerated, raising no significant clinical issues in humans at doses significantly higher than doses to be used in upcoming clinical trials in patients.